Authored By: Sarah
13 Nov 2024

increase in pet humanization is driving the Canine Atopic Dermatitis Market

Latest News:- Canine Atopic Dermatitis Market: Antihistamines is expected to lead the Product segment during 2024-2028

Technavio analyzes that the Canine Atopic Dermatitis Market is expected to grow at a CAGR of 5.8% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 231.3 million.There are various factors that contribute to the growth of the market. The Canine Atopic Dermatitis market is experiencing significant growth due to the increasing trend of pet humanization. As pets are considered as family members, their health and well-being are prioritized, leading to a rise in demand for effective treatments for conditions like canine atopic dermatitis. This chronic skin condition affects dogs, causing itching, inflammation, and skin lesions. The market for treatments, including pharmaceuticals, nutraceuticals, and therapeutic foods, is expected to expand as pet owners seek to alleviate their furry companions' discomfort.

Canine Atopic Dermatitis Market: Antihistamines as a Treatment Option for Allergic Skin Conditions in Dogs Antihistamines, a class of drugs commonly used to alleviate symptoms of allergic reactions in humans, have gained significance in the canine atopic dermatitis market. These medications inhibit histamine type 1 (H1) receptors, which are present in smooth muscles in the bronchi, gastrointestinal tract, uterus, and large blood vessels. Antihistamines are primarily employed to mitigate symptoms of allergic conditions, including itching, runny nose, nasal stuffiness, urticaria, teary eyes, dizziness, cough, and nausea. However, their adoption in pet healthcare is subject to certain considerations. Side effects such as sedation, impaired motor function, dry mouth and throat, dizziness, blurred vision, constipation, and urinary retention may hinder the use of antihistamines in treating canine atopic dermatitis. Consequently, the development of topical treatments, oral administrations, and injectable treatments has emerged as a viable alternative to antihistamines. These newer treatment modalities aim to minimize side effects while ensuring treatment efficacy. The veterinary hospitals and retail distribution channels serve as crucial touchpoints for the sale and distribution of canine atopic dermatitis treatments. The growing pet healthcare expenditure, coupled with the increasing awareness of animal welfare, is expected to fuel market growth. Clinical studies evaluating the safety and efficacy of various treatment options continue to be a priority for market participants. In conclusion, the canine atopic dermatitis market presents a promising landscape for innovation, with a focus on developing effective and side-effect-minimizing treatments for allergic skin conditions in dogs. 

Know which region is leading the market growth by requesting a sample report

Canine Atopic Dermatitis Market Segmentation

  • Product
    • Antihistamines
    • Glucocorticoids
    • Progestational compounds
    • Others
  • Geography
    • North America
    • Europe
    • Asia
    • Rest of World (ROW)

Top Performing Companies

As per our research findings, here are some of the key competitors that are leading the industry

  • AB Science SA
  • Bimeda Holdings Ltd.
  • Bioceltix Spolka Akcyjna
  • Bioiberica S.A.U.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Dechra Pharmaceuticals Plc
  • Elanco Animal Health Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Toray Industries Inc.
  • Vetoquinol UK Ltd.
  • Vimian Group AB
  • Virbac Group
  • Zoetis Inc.

Find out what is trending in the market by accessing the free PDF report

Research Analysis Overview

Canine Atopic Dermatitis Market: Trends and Treatments Canine Atopic Dermatitis (CAD) is a chronic health issue characterized by itchy skin, chronic pruritis, and skin lesions caused by IgE antibodies in response to environmental allergens. Treatment options include Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies, and Off-label Drugs. Veterinary Practitioners often prescribe these treatments, while Pet Insurance coverage can help offset costs. Genetic abnormalities and health issues may influence CAD development. Newer treatments like Stem cell therapy, Platelet-rich Plasma (PRP), Cytopoint (lokivetmab), Oclacitinib Maleate (Apoquel), and Regenerative medicines are gaining popularity. Veterinary Pharmaceuticals and E-commerce platforms offer these treatments, with Monoclonal Antibodies and Immunosuppressants among the most commonly used. Environmental allergens, such as pollen, dust mites, and mold, trigger CAD, while pet ownership and veterinary care continue to rise, driving market growth. Itchy skin remains a significant concern for dog owners, making effective and affordable treatments essential.

Market Research Overview

The Canine Atopic Dermatitis market is a significant segment within the global pharmaceuticals industry, encompassing entities involved in the research and development (R&D) or production of veterinary drugs, including glucocorticoids, antihistamines, immunosuppressants, and monoclonal antibodies. Factors driving market growth include the rise in pet insurance coverage, increasing prevalence of environmental allergens, and the growing number of veterinary practitioners. Genetic abnormalities and the development of monoclonal antibodies also contribute to market expansion. The global pharmaceuticals market, which includes manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services, is expected to grow due to demographic trends, with a substantial increase in the aging population in regions such as Europe and the US.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Reasons to Consider Purchasing Technavio Market Research Report

  • Current Market Insights: Our reports offer valuable information on the latest market intelligence, competitor strategies, trends, industry changes, customer preferences, and forecasted market opportunities to aid in informed business decisions.

  • Extensive Experience: With over 20 years in market research, Technavio is a trusted name, having published more than 21,000 reports across various industries and regions.

  • High ROI Through In-Depth Research: Technavio specializes in tailored market research reports to meet specific business needs, exploring particular markets, product segments, and demographics. We are also recognized for delivering significant returns on investment through our comprehensive data collection at affordable prices.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!

Safe and Secure SSL Encrypted

Technavio

  • 2500 USD

[5 reports/month/user]

  • 5000 USD

close
  • Basic Plan [5000 USD/Year]:

    Single User
    Download 5 Reports/Month
    View 100 Reports/Month
    Add upto 3 Users at 625 USD/user

  • Teams Plan [7500 USD/Year]:

    5 User
    Download 5 Reports/Month/User
    View 100 Reports/Month/User
    Add upto 30 Users at 500 USD/user

*You can upgrade to Teams plan at Subscription page

close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization).
    Complimentary Customization Included

*For Enterprise license, go to checkout page

Technavio Get the report (PDF) sent to your email within minutes.